Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Biofrontera Inc. stock (symbol: BFRI) underwent a total of 1 stock splits.
The most recent stock split occured on Jul 05, 2023.
Date | Splite | Multiple |
---|---|---|
2023-07-05 | 1:20 | 1 |